Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ⅱ Randomized Controlled Proof-of-concept Study to Evaluate the Safety and Efficacy of JINZHEN Granules for Oral Solution in Participants With Mild to Moderate COVID-19

NCT05092503 is registered in ClinicalTrials.gov with Lianyungang Kanion Group, Ltd. as lead sponsor.

NCT NCT05092503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ⅱ Randomized Controlled Proof-of-concept Study to Evaluate the Safety and Efficacy of JINZHEN Granules for Oral Solution in Participants With Mild to Moderate COVID-19
Lead sponsor
Lianyungang Kanion Group, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
May 26, 2022
Completion date
May 12, 2023
Enrollment
60 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19